Dr. Reddy’s Listed on Dow Jones Sustainability Indices 2016
September 13 2016 - 05:35AM
Business Wire
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE:
RDY) has been listed as an Index component of the Dow Jones
Sustainability Indices (DJSI) 2016 in the Pharmaceuticals,
Biotechnology & Life Sciences Industry Group. The Company has
been recognized for its corporate sustainability leadership and is
the only pharmaceutical company on the Index of Emerging
Markets.
The listing was based on 22 criteria, with Dr. Reddy’s receiving
high scores for Product Quality and Recall Management, Codes of
Business Conduct, Environmental Reporting, Corporate Citizenship
and Philanthropy.
G V Prasad, Co-Chairman and CEO, Dr. Reddy’s Laboratories, said,
"Over the years, Dr. Reddy’s has evolved into a global organization
built on the foundation of responsible business practices. This has
earned us the trust and respect of all the stakeholders we serve. I
see our inclusion in the Dow Jones Sustainability Indices as
another validation of our commitment to sustainability in all
aspects of our business.’’
The Dow Jones Sustainability Indices is the foremost global
benchmark for corporate sustainability. DJSI tracks leading
sustainability-driven companies based on the analysis of
financially relevant environmental, social and governance
factors.
About Dr. Reddy’s: Dr. Reddy’s Laboratories Ltd. (BSE:
500124, NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical
company, committed to providing affordable and innovative medicines
for healthier lives. Through its three businesses – Pharmaceutical
Services & Active Ingredients, Global Generics and Proprietary
Products – Dr. Reddy’s offers a portfolio of products and services
including APIs, custom pharmaceutical services, generics,
biosimilars and differentiated formulations. Our major therapeutic
areas of focus are gastrointestinal, cardiovascular, diabetology,
oncology, pain management and dermatology. Dr. Reddy’s operates in
markets across the globe. Our major markets include – USA, India,
Russia & CIS countries, and Europe. For more information, log
on to: www.drreddys.com
Disclaimer: This press release may include statements of
future expectations and other forward-looking statements that are
based on the management’s current views and assumptions and involve
known or unknown risks and uncertainties that could cause actual
results, performance or events to differ materially from those
expressed or implied in such statements. In addition to statements
which are forward-looking by reason of context, the words "may,"
"will," "should," "expects," "plans," "intends," "anticipates,"
"believes," "estimates," "predicts," "potential," or "continue" and
similar expressions identify forward-looking statements. Actual
results, performance or events may differ materially from those in
such statements due to without limitation, (i) general economic
conditions such as performance of financial markets, credit
defaults, currency exchange rates, interest rates, persistency
levels and frequency/severity of insured loss events, (ii)
mortality and morbidity levels and trends, (iii) changing levels of
competition and general competitive factors, (iv) changes in laws
and regulations and in the policies of central banks and/or
governments, (v) the impact of acquisitions or reorganization,
including related integration issues.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160913005806/en/
Dr. Reddy’s Laboratories Ltd.INVESTOR
RELATIONSSaunak Savla,
+91-40-49002135saunaks@drreddys.comorMEDIA RELATIONSCalvin
Printer, +91-40-49002121calvinprinter@drreddys.com
Dr Reddys Laboratories (NYSE:RDY)
Historical Stock Chart
From Feb 2024 to Mar 2024
Dr Reddys Laboratories (NYSE:RDY)
Historical Stock Chart
From Mar 2023 to Mar 2024